Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Savara Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03181932CT.gov AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis | — | Completed | — | — | — |
NCT01746095CT.gov Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients | — | Completed | — | — | — |
NCT01594827CT.gov Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) | — | Completed | — | — | — |
NCT01509339CT.gov Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cystic Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vancomycin (this asset) | Savara Inc. | P3 | B · 61 |
| Tezacaftor | Vertex Pharmaceuticals Incorporated | P4 | A |
| Ivacaftor | Meyer Children's Hospital IRCCS | P4 | A |
| Liprotamase | Anthera Pharmaceuticals | P4 | BBB |
| Lumacaftor | Hospices Civils de Lyon | P4 | BBB |
| Elexacaftor | Meyer Children's Hospital IRCCS | P4 | BBB |
| vx-121 | Vertex Pharmaceuticals Incorporated | P3 | BBB |
| Azithromycin | Hospices Civils de Lyon | P4 | BBB |
| Colistin | Liverpool Heart and Chest Hospital NHS Foundation Trust | P4 | BBB |
+42 more in the Cystic Fibrosis cohort
Other indications for Vancomycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Sclerosing Cholangitis | — | P4 | BB · 69 |
| Methicillin-Resistant Staphylococcus Aureus Infectious Disease | — | P3 | BB · 64 |
| Childhood Neoplasm | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vancomycin in Cystic Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vancomycin-cystic-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →